Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintaining or Stopping Immunosuppressive Therapy in ANCA Vasculitis with End-stage Renal Disease
2024-512470-10-00Phase 4Authorised
- Sponsor
- CHD Vendée
- Start
- Apr 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rituximab, prednisone, azathioprine, mycophenolate mofetil and mycophenolic acid in granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and end-stage kidney disease (ESKD) (2 arms), sponsored by CHD Vendée. Primary endpoint: Time to first severe prejudicial event. Planned start Apr 2024; status: authorised.
02
Drugs
rituximabprednisoneazathioprinemycophenolate mofetilmycophenolic acid
03
Conditions
granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-512470-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512470-10-00.